These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 10384859)

  • 21. 'In vitro' study of chemotherapeutic activity of sulphimidazole on some sensitive and metronidazole-resistant Trichomonas vaginalis strains.
    Malagoli M; Rossi T; Baggio A; Zandomeneghi G; Zanca A; Casolari C; Castelli M
    Pharmacol Res; 2002 Nov; 46(5):469-72. PubMed ID: 12419652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis.
    Nix DE; Tyrrell R; Müller M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1848-52. PubMed ID: 7486930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial, antimycotic and trichomonicidal activity of a new nitroimidazole (EU 11100).
    Dubini F; Riviera L; Cocuzza C; Bellotti MG
    J Chemother; 1992 Dec; 4(6):342-6. PubMed ID: 1287136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic considerations in the treatment of inflammatory bowel disease.
    Schwab M; Klotz U
    Clin Pharmacokinet; 2001; 40(10):723-51. PubMed ID: 11707060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
    Davies NM; McLachlan AJ; Day RO; Williams KM
    Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.
    Aminimanizani A; Beringer P; Jelliffe R
    Clin Pharmacokinet; 2001; 40(3):169-87. PubMed ID: 11327197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitroimidazoles in the treatment of trichomoniasis, giardiasis, and amebiasis.
    Rossignol JF; Maisonneuve H; Cho YW
    Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):63-72. PubMed ID: 6698665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metronidazole pharmacokinetics in geese (Anser anser domesticus) after intravenous and oral administrations.
    Fadel C; Łebkowska-Wieruszewska B; Bourdo K; Poapolathep A; Hassoun G; Giorgi M
    J Vet Pharmacol Ther; 2024 May; 47(3):208-214. PubMed ID: 38032073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disposition of metronidazole in hens (Gallus gallus) and quails (Coturnix coturnix japonica): pharmacokinetics and whole-body autoradiography.
    Cybulski W; Larsson P; Tjälve H; Kowalska-Pylka H; Sylla M; Semeniuk S
    J Vet Pharmacol Ther; 1996 Oct; 19(5):352-8. PubMed ID: 8905568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
    Shi J; Montay G; Bhargava VO
    Clin Pharmacokinet; 2005; 44(9):915-34. PubMed ID: 16122280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tinidazole: from protozoa to Helicobacter pylori--the past, present and future of a nitroimidazole with peculiarities.
    Manes G; Balzano A
    Expert Rev Anti Infect Ther; 2004 Oct; 2(5):695-705. PubMed ID: 15482233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term sucralfate administration does not alter the absorption of metronidazole in healthy male volunteers.
    Moraes ME; Pierossi Mde A; Moraes MO; Bezerra FF; Da Silva CM; Dias HB; Muscará MN; De Nucci G; Pedrazzoli Júnior J
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):433-7. PubMed ID: 8897081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma and skin blister fluid concentrations of metronidazole and its hydroxy metabolite after oral administration.
    Klimowicz A; Nowak A; Bielecka-Grzela S
    Pol J Pharmacol; 1996; 48(1):47-52. PubMed ID: 9112627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of metronidazole in rabbits after administration of a rectal suppository.
    Ofoefule SI; Ibezim EC; Esimone OC; Pepple MN; Njoku CN; Orisakwe EO
    Am J Ther; 2004; 11(3):190-3. PubMed ID: 15133533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility of anaerobic bacteria to metronidazole, ornidazole, and tinidazole and routine susceptibility testing by standardized methods.
    Wust J
    Antimicrob Agents Chemother; 1977 Apr; 11(4):631-7. PubMed ID: 856015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic optimisation of treatment with oral etoposide.
    Toffoli G; Corona G; Basso B; Boiocchi M
    Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of Campylobacter species to metronidazole, its bioactive metabolites and tinidazole.
    Bannatyne RM; Jackowski J; Karmali MA
    Infection; 1987; 15(6):457-8. PubMed ID: 3436679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.